CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-12-30 | SCHIERMEIER ANDREW EVP, Chief Operating Officer | Option exercise | +1,500 | $13.48 | $20K | 12,673 |
| 2020-12-30 | SCHIERMEIER ANDREW EVP, Chief Operating Officer | Option exercise · Stock Option (right to buy) | −1,500 | 148,500 | ||
| 2020-12-17 | KARSEN PERRY A Director | Option exercise | +31,764 | $18.00 | $572K | 36,764 |
| 2020-12-17 | KARSEN PERRY A Director | Option exercise | +19,000 | $14.35 | $273K | 55,764 |
| 2020-12-17 | KARSEN PERRY A Director | Option exercise | +19,000 | $25.98 | $494K | 74,764 |
| 2020-12-17 | KARSEN PERRY A Director | Option exercise | +19,000 | $15.78 | $300K | 93,764 |
| 2020-12-17 | KARSEN PERRY A Director | Sale | −21,978 | $52.52 | $1.2M | 71,786 |
| 2020-12-17 | KARSEN PERRY A Director | Sale | −45,450 | $53.69 | $2.4M | 26,336 |
| 2020-12-17 | KARSEN PERRY A Director | Sale | −21,336 | $54.33 | $1.2M | 5,000 |
| 2020-12-17 | KARSEN PERRY A Director | Option exercise · Stock Option (right to buy) | −31,764 | 0 | ||
| 2020-12-17 | KARSEN PERRY A Director | Option exercise · Stock Option (right to buy) | −19,000 | 0 | ||
| 2020-12-17 | KARSEN PERRY A Director | Option exercise · Stock Option (right to buy) | −19,000 | 0 | ||
| 2020-12-17 | KARSEN PERRY A Director | Option exercise · Stock Option (right to buy) | −19,000 | 0 | ||
| 2020-12-01 | Rivera Jose E EVP, General Counsel | Option exercise | +5,000 | $13.88 | $69K | 52,072 |
| 2020-12-01 | Rivera Jose E EVP, General Counsel | Sale | −1,585 | $37.73 | $60K | 50,487 |
| 2020-12-01 | Rivera Jose E EVP, General Counsel | Sale | −1,522 | $38.49 | $59K | 48,965 |
| 2020-12-01 | Rivera Jose E EVP, General Counsel | Sale | −257 | $39.46 | $10K | 48,708 |
| 2020-12-01 | Rivera Jose E EVP, General Counsel | Option exercise · Stock Option (right to buy) | −5,000 | 105,000 | ||
| 2020-11-27 | LEONARD JOHN M President and CEO | Option exercise | +15,000 | $18.30 | $275K | 482,352 |
| 2020-11-27 | LEONARD JOHN M President and CEO | Sale | −15,000 | $38.00 | $570K | 467,352 |
Page 29 of 40 · 783 trades